Red Cedar Capital’s AbbVie ABBV Stock Holding History

Red Cedar Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$429K	Sell	2,652 -124	-4%	-$19K	0.27%	46
2022 Q3	$373K	Hold	2,776	–	–	0.26%	50
2022 Q2	$425K	Hold	2,776	–	–	0.29%	49
2022 Q1	$450K	Hold	2,776	–	–	0.27%	47
2021 Q4	$376K	Hold	2,776	–	–	0.21%	51
2021 Q3	$299K	Hold	2,776	–	–	0.18%	52
2021 Q2	$313K	Hold	2,776	–	–	0.2%	52
2021 Q1	$300K	Buy	2,776 +13	+0.5%	+$1.39K	0.2%	52
2020 Q4	$296K	Hold	2,763	–	–	0.22%	51
2020 Q3	$242K	Hold	2,763	–	–	0.21%	55
2020 Q2	$271K	Hold	2,763	–	–	0.25%	51
2020 Q1	$211K	Sell	2,763 -233	-8%	-$19.8K	0.21%	55
2019 Q4	$265K	Hold	2,996	–	–	0.2%	54
2019 Q3	$227K	Hold	2,996	–	–	0.19%	58
2019 Q2	$218K	Hold	2,996	–	–	0.18%	61
2019 Q1	$241K	Hold	2,996	–	–	0.21%	53
2018 Q4	$276K	Hold	2,996	–	–	0.27%	50
2018 Q3	$283K	Hold	2,996	–	–	0.25%	51
2018 Q2	$278K	Hold	2,996	–	–	0.25%	53
2018 Q1	$284K	Hold	2,996	–	–	0.26%	52
2017 Q4	$290K	Buy	+2,996	New	+$282K	0.24%	51

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Red Cedar Capital's ABBV Position: Q4 2022 in Review

Red Cedar Capital reduced its AbbVie (ABBV) stake by 4.5% in Q4 2022, selling an estimated $19K and leaving 2,652 shares worth $429K. The position accounts for 0.27% of the portfolio, ranked #46.

Red Cedar Capital first reported a position in ABBV in Q4 2017 and has held it in 21 quarters since. The position peaked at $450K in Q1 2022. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Red Cedar Capital held 2,652 shares of AbbVie worth $429K as of Q4 2022.
Red Cedar Capital sold 124 AbbVie shares in Q4 2022, an estimated $19K.
AbbVie made up 0.27% of Red Cedar Capital's portfolio in Q4 2022, its #46 holding.
Red Cedar Capital first reported a position in AbbVie in Q4 2017 and has held it in 21 quarters since.
Red Cedar Capital's AbbVie position peaked at $450K in Q1 2022.
3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Red Cedar Capital's 13F filing for Q4 2022, filed 6 Feb 2023.